Selected article for: "study period and symptom onset"

Author: Sherina, Natalia; Piralla, Antonio; Du, Likun; Wan, Hui; Kumagai-Braesh, Makiko; Andréll, Juni; Braesch-Andersen, Sten; Cassaniti, Irene; Percivalle, Elena; Sarasini, Antonella; Bergami, Federica; Di Martino, Raffaella; Colaneri, Marta; Vecchia, Marco; Sambo, Margherita; Zuccaro, Valentina; Bruno, Raffaele; Oggionni, Tiberio; Meloni, Federica; Abolhassani, Hassan; Bertoglio, Federico; Schubert, Maren; Byrne-Steele, Miranda; Han, Jian; Hust, Michael; Xue, Yintong; Hammarström, Lennart; Baldanti, Fausto; Marcotte, Harold; Pan-Hammarström, Qiang
Title: Persistence of SARS-CoV-2 specific B- and T-cell responses in convalescent COVID-19 patients 6-8 months after the infection
  • Cord-id: 8jbisapd
  • Document date: 2020_11_6
  • ID: 8jbisapd
    Snippet: Background The longevity of the immune response against SARS-CoV-2 is currently debated. We thus profiled the serum anti-SARS-CoV-2 antibody levels and virus specific memory B- and T-cell responses over time in convalescent COVID-19 patients. Methods A cohort of COVID-19 patients from the Lombardy region in Italy who experienced mild to critical disease and Swedish volunteers with mild symptoms, were tested for the presence of elevated anti-spike and anti-receptor binding domain antibody levels
    Document: Background The longevity of the immune response against SARS-CoV-2 is currently debated. We thus profiled the serum anti-SARS-CoV-2 antibody levels and virus specific memory B- and T-cell responses over time in convalescent COVID-19 patients. Methods A cohort of COVID-19 patients from the Lombardy region in Italy who experienced mild to critical disease and Swedish volunteers with mild symptoms, were tested for the presence of elevated anti-spike and anti-receptor binding domain antibody levels over a period of eight months. In addition, specific memory B- and T-cell responses were tested in selected patient samples. Results Anti-SARS-CoV-2 antibodies were present in 85% samples collected within 4 weeks after onset of symptoms in COVID-19 patients. Levels of specific IgM or IgA antibodies declined after 1 month while levels of specific IgG antibodies remained stable up to 6 months after diagnosis. Anti-SARS-CoV-2 IgG antibodies were still present, though at a significantly lower level, in 80% samples collected at 6-8 months after symptom onset. SARS-CoV-2-specific memory B- and T-cell responses were developed in vast majority of the patients tested, regardless of disease severity, and remained detectable up to 6-8 months after infection. Conclusions Although the serum levels of anti-SARS-CoV-2 IgG antibodies started to decline, virus-specific T and/or memory B cell responses increased with time and maintained during the study period (6-8 months after infection). Funding European Union’s Horizon 2020 research and innovation programme (ATAC), the Italian Ministry of Health, CIMED, the Swedish Research Council and the China Scholarship Council.

    Search related documents:
    Co phrase search for related documents
    • adaptive immune response and long protective term: 1
    • adaptive immune response and long protective term immunity: 1
    • adaptive immune response and long term immunity: 1, 2
    • adaptive immune response and long term protection: 1, 2, 3
    • adaptive immune response and long term protective immunity: 1
    • adaptive immunity and long period: 1
    • adaptive immunity and long protective: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • adaptive immunity and long protective term: 1, 2, 3, 4, 5, 6, 7
    • adaptive immunity and long protective term immunity: 1, 2, 3, 4, 5, 6
    • adaptive immunity and long term immunity: 1, 2, 3, 4, 5, 6, 7
    • adaptive immunity and long term protection: 1, 2
    • adaptive immunity and long term protective immunity: 1, 2, 3, 4, 5, 6
    • adaptive immunity and long term protective immunity development: 1
    • adaptive immunity and low prevalence: 1, 2
    • long duration and low prevalence: 1, 2
    • long interval and low prevalence: 1
    • long period and low prevalence: 1, 2, 3
    • long protective and low prevalence: 1
    • long term immunity and low prevalence: 1